Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma. It is also developing AUTO4, a programmed T cell therapy that is in Phase I/II clinical trial for the treatment of peripheral T-cell lymphoma; and AUTO6, a programmed T cell therapy for treating neuroblastoma. Autolus Therapeutics plc has a collaboration partnership with AbCellera Biologics Inc. on antibody discovery project. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone44-20-3829-6230
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.41 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions
What is Autolus Therapeutics' stock symbol?
Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."
What price target have analysts set for AUTL?
5 Wall Street analysts have issued twelve-month target prices for Autolus Therapeutics' stock. Their predictions range from $37.00 to $50.00. On average, they anticipate Autolus Therapeutics' share price to reach $44.00 in the next twelve months. This suggests a possible upside of 74.7% from the stock's current price. View Analyst Price Targets for Autolus Therapeutics.
What is the consensus analysts' recommendation for Autolus Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Autolus Therapeutics.
What are Wall Street analysts saying about Autolus Therapeutics stock?
Here are some recent quotes from research analysts about Autolus Therapeutics stock:
- 1. According to Zacks Investment Research, "Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom. " (1/15/2019)
- 2. HC Wainwright analysts commented, "We envision upside to our target if the upcoming data reflect the anticipated advantages of Autolus’ CAR T assets. Our $45 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF model. Our DCF is based on: beta of 1.45, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.2%, and tax rate of 15% beginning in FY 2027." (11/2/2018)
Has Autolus Therapeutics been receiving favorable news coverage?
Media coverage about AUTL stock has trended somewhat positive on Friday, InfoTrie reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Autolus Therapeutics earned a coverage optimism score of 1.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the immediate future.
Who are some of Autolus Therapeutics' key competitors?
Some companies that are related to Autolus Therapeutics include Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX) and Alector (ALEC).
What other stocks do shareholders of Autolus Therapeutics own?
Who are Autolus Therapeutics' key executives?
Autolus Therapeutics' management team includes the folowing people:
- Dr. Christian Martin Itin, Chairman & CEO (Age 55)
- Dr. Martin Pulé, Founder, Sr. VP & Chief Scientific Officer (Age 47)
- Mr. Andrew J. Oakley, CFO & Sr. VP (Age 57)
- Mr. Christopher Vann, Sr. VP & COO (Age 55)
- Mr. Matthias Alder, Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 54)
When did Autolus Therapeutics IPO?
(AUTL) raised $125 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.
Who are Autolus Therapeutics' major shareholders?
Autolus Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Artal Group S.A. (1.18%), Sphera Funds Management LTD. (0.51%), BlackRock Inc. (0.51%), Jennison Associates LLC (0.27%), Victory Capital Management Inc. (0.11%) and Nuveen Asset Management LLC (0.07%).
Which major investors are selling Autolus Therapeutics stock?
AUTL stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Victory Capital Management Inc., Artal Group S.A., Millennium Management LLC, Jennison Associates LLC, Nuveen Asset Management LLC, Weiss Multi Strategy Advisers LLC and Bank of Montreal Can.
Which major investors are buying Autolus Therapeutics stock?
AUTL stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Geode Capital Management LLC, Virtus ETF Advisers LLC and Barclays PLC.
How do I buy shares of Autolus Therapeutics?
Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Autolus Therapeutics' stock price today?
One share of AUTL stock can currently be purchased for approximately $25.19.
How big of a company is Autolus Therapeutics?
Autolus Therapeutics has a market capitalization of $1.01 billion and generates $1.41 million in revenue each year. The company earns $-44,750,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis.
What is Autolus Therapeutics' official website?
How can I contact Autolus Therapeutics?
Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 44-20-3829-6230 or via email at [email protected]
MarketBeat Community Rating for Autolus Therapeutics (NASDAQ AUTL)
MarketBeat's community ratings are surveys of what our community members think about Autolus Therapeutics and other stocks. Vote "Outperform" if you believe AUTL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUTL will underperform the S&P 500 over the long term. You may vote once every thirty days.
